Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Quaini

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Molecular Cancer|June 6, 2014
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Francesca Saccani, Federico Quaini, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 20, 2016
Antiarrhythmic effect of growth factor-supplemented cardiac progenitor cells in chronic infarcted heartMonia Savi, Leonardo Bocchi, Stefano Rossi, et al.
Circulation Research|December 1, 2004
Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusionJan Kajstura, Marcello Rota, Brian Whang, et al.
International Journal of Molecular Sciences|January 10, 2026
In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat ModelVanessa Pitozzi, Paola Lorenza Caruso, Silvia Pontis, et al.
Journal of Thoracic Imaging|August 27, 2024
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint InhibitorsMaurizio Balbi, Giulia Mazzaschi, Ludovica Leo, et al.
Tumori|May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitorsRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneityMelissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
Oncotarget|December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Tumori|March 18, 2021
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patientsFrancesca Trentini, Giulia Mazzaschi, Gianluca Milanese, et al.
Immunotherapy|August 6, 2024
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapyFabiana Perrone, Federica Pecci, Michele Maffezzoli, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Molecular Cancer|June 6, 2014
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Francesca Saccani, Federico Quaini, et al.
American Journal of Physiology. Heart and Circulatory Physiology|March 20, 2016
Antiarrhythmic effect of growth factor-supplemented cardiac progenitor cells in chronic infarcted heartMonia Savi, Leonardo Bocchi, Stefano Rossi, et al.
Circulation Research|December 1, 2004
Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusionJan Kajstura, Marcello Rota, Brian Whang, et al.
International Journal of Molecular Sciences|January 10, 2026
In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat ModelVanessa Pitozzi, Paola Lorenza Caruso, Silvia Pontis, et al.
Journal of Thoracic Imaging|August 27, 2024
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint InhibitorsMaurizio Balbi, Giulia Mazzaschi, Ludovica Leo, et al.
Tumori|May 18, 2021
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitorsRoberta Minari, Francesco Bonatti, Giulia Mazzaschi, et al.
Exploration of Targeted Anti-Tumor Therapy|September 18, 2023
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneityMelissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, et al.
Oncotarget|December 2, 2017
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolismClaudia Fumarola, Daniele Cretella, Silvia La Monica, et al.
Tumori|March 18, 2021
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patientsFrancesca Trentini, Giulia Mazzaschi, Gianluca Milanese, et al.
Immunotherapy|August 6, 2024
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapyFabiana Perrone, Federica Pecci, Michele Maffezzoli, et al.
Pageof 11